Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer
- 30 November 2004
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 46 (2) , 247-254
- https://doi.org/10.1016/j.lungcan.2004.04.032
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumorsAnnals of Oncology, 2003
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With CisplatinJournal of Clinical Oncology, 2000
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- ZD1839 (???Iressa???)*,??? as an Anticancer AgentDrugs, 2000
- Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomasBritish Journal of Cancer, 1998
- Revisions in the International System for Staging Lung CancerChest, 1997
- A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancerEuropean Journal Of Cancer, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995